Intake of polyunsaturated fat in relation to mortality among statin users and non-users in the Southern Community Cohort Study

Published on Nov 1, 2015in Nutrition Metabolism and Cardiovascular Diseases3.34
· DOI :10.1016/j.numecd.2015.07.006
J. N. Kiage1
Estimated H-index: 1
(VUMC: Vanderbilt University Medical Center),
Uchechukwu Sampson34
Estimated H-index: 34
+ 8 AuthorsEdmond K. Kabagambe37
Estimated H-index: 37
(VUMC: Vanderbilt University Medical Center)
Abstract Background and aims Consumption of polyunsaturated fatty acids (PUFA), especially the n3-series, may protect against cardiovascular disease (CVD), but recent randomized studies have failed to demonstrate these benefits. One of the prevailing hypotheses is that PUFA intake may not confer benefits beyond those provided by statins, but studies comparing statin users to non-users with regard to effects of PUFA are lacking. Methods and results Black and white men and women (n = 69,559) in the Southern Community Cohort Study were studied. Cox regression models adjusting for age, sex, race, BMI, recruitment site, education, income, smoking, diabetes, and dietary variables were used. Results At baseline the mean ± SD age was 52 ± 9 years, 60% of participants were women, 54% had hypertension and 16% used statins. We observed modest inverse associations between n3-PUFA and n6-PUFA intake with mortality among non-statin users but not among statin users. In adjusted analyses, the HRs (95% CIs) for all-cause mortality (6,396 deaths over a median of 6.4 years) comparing the highest to the lowest quintile were 0.90 (0.82–1.00) for n3-PUFA and 0.80 (0.70–0.92) for n6-PUFA among non-statin users, whereas they were 1.06 (0.87–1.28) and 0.96 (0.78–1.19) for n3-PUFA and n6-PUFA, respectively, among statin users. Conclusions Our results suggest potential benefits of PUFA consumption on mortality which are only apparent in the absence of statin therapy. It seems prudent to consider the potential benefit of PUFA consumption in the primary prevention of CVD among patients who are not candidates for statin therapy but are at increased risk for CVD and mortality.
Figures & Tables
  • References (44)
  • Citations (8)
#1Loren Lipworth (VUMC: Vanderbilt University Medical Center)H-Index: 39
#2Henry Okafor (Meharry Medical College)H-Index: 5
Last.Dawood Darbar (VUMC: Vanderbilt University Medical Center)H-Index: 39
view all 7 authors...
#1Luis I. Juncos (CONICET: National Scientific and Technical Research Council)H-Index: 2
#2Luis A. Juncos (UMMC: University of Mississippi Medical Center)H-Index: 29
Last.Nestor H Garcia (CONICET: National Scientific and Technical Research Council)H-Index: 5
view all 3 authors...
Cited By8
#1Ryan S. Hsi (VUMC: Vanderbilt University Medical Center)H-Index: 17
#2Edmond K. Kabagambe (VUMC: Vanderbilt University Medical Center)H-Index: 37
Last.Loren Lipworth (VUMC: Vanderbilt University Medical Center)H-Index: 39
view all 6 authors...
#1Rakesh Malhotra (UCSD: University of California, San Diego)H-Index: 24
#2Kerri L. Cavanaugh (Vandy: Vanderbilt University)H-Index: 24
Last.Edmond K. Kabagambe (Vandy: Vanderbilt University)H-Index: 37
view all 6 authors...
View next paperAbstract 20129: Polyunsaturated Fat Intake Estimated by Circulating Biomarkers is Inversely Associated with Cardiovascular Disease and All-Cause Mortality in a Large Population-Based Cohort of Swedish Women and Men